Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
This invention is directed to methods of treating diseases or conditions associated with JAK2 activity in a mammal comprising the administration of a compound of formula (I): where n, m, Y, R 1 , R 2 , R 3 , R 4 and R 5 are disclosed herein, or a pharmaceutically acceptable salt.
1. A method of treating, but not preventing, a disease or condition associated with JAK2 activity in a mammal, wherein the method comprises administering to the mammal a therapeutically effective amount of 4-(6-(morpholin-4-yl)pyridin-3-yl)-N-(3-methyl-4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)pyrimidin-2-amine, or a pharmaceutically acceptable salt thereof, and the disease or condition is polycythemia vera disorder, essential thrombocythemia disorder or primary myelofibrosis.
2. A method of treating, but not preventing, a disease or condition associated with JAK2 activity in a mammal, wherein the method comprises administering to the mammal a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of 4-(6-(morpholin-4-yl)pyridin-3-yl)-N-(3-methyl-4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)pyrimidin-2-amine, or a pharmaceutically acceptable salt thereof, and the disease or condition is polycythemia vera disorder, essential thrombocythemia disorder or primary myelofibrosis.
3. The method of claim 1 wherein the disease or condition is polycythemia vera disorder.
4. The method of claim 1 wherein the disease or condition is essential thrombocythemia disorder.
5. The method of claim 1 wherein the disease or condition is primary myelofibrosis.
6. The method of claim 2 wherein the disease or condition is polycythemia vera disorder.
7. The method of claim 2 wherein the disease or condition is essential thrombocythemia disorder.
8. The method of claim 2 wherein the disease or condition is primary myelofibrosis.